Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

[1] Yamanaka H(2014)Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I) Mod Rheumatol 24 33-40

[2] Sugiyama N(2003)Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) Ann Rheum Dis 62 2-9

[3] Inoue E(2013)Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks Ann Rheum Dis 72 1488-1495

[4] Taniguchi A(2012)Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study Ann Rheum Dis 71 817-824

[5] Momohara S(2009)Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: 24-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 2272-2283

[6] Furst DE(2009)Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 210-221

[7] Breedveld FC(2009)Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 68 789-796

[8] Kalden JR(2016)Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: post hoc analysis of the GO-FORTH study Mod Rheumatol 26 323-330

[9] Takeuchi T(2018)Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients Rheumatol Ther. 5 185-201

[10] Harigai M(2016)Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data Clin Ther 38 1359-1375

[1] Yamanaka H(2014)Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I) Mod Rheumatol 24 33-40

[2] Sugiyama N(2003)Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) Ann Rheum Dis 62 2-9

[3] Inoue E(2013)Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks Ann Rheum Dis 72 1488-1495

[4] Taniguchi A(2012)Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study Ann Rheum Dis 71 817-824

[5] Momohara S(2009)Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: 24-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 2272-2283

[6] Furst DE(2009)Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 210-221

[7] Breedveld FC(2009)Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 68 789-796

[8] Kalden JR(2016)Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: post hoc analysis of the GO-FORTH study Mod Rheumatol 26 323-330

[9] Takeuchi T(2018)Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients Rheumatol Ther. 5 185-201

[10] Harigai M(2016)Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data Clin Ther 38 1359-1375